Janus Kinase (JAK) Inhibitor
Deucravacitinib for Psoriatic Arthritis
This trial is testing a new medication called deucravacitinib to see if it can help people with psoriatic arthritis who haven't tried advanced treatments. The medication works by reducing joint swelling and pain by blocking inflammation. Deucravacitinib is a new oral drug that has shown good results in previous studies for psoriasis.
Janus Kinase (JAK) Inhibitor
Deucravacitinib for Psoriatic Arthritis
This trial is testing a new medication called deucravacitinib to help people with active Psoriatic Arthritis. It aims to reduce joint pain and swelling by blocking harmful signals in the body. The study includes people who haven't tried biologic treatments or need an alternative to TNFα inhibitors. Deucravacitinib is an emerging treatment option for Psoriatic Arthritis, showing promise in recent studies.
Monoclonal Antibodies
Tildrakizumab for Psoriatic Arthritis
This trial is testing tildrakizumab, a medication that reduces inflammation, in patients with active Psoriatic Arthritis who haven't tried certain other treatments. It works by blocking a protein to help manage symptoms. Tildrakizumab is approved for treating moderate to severe plaque psoriasis.
Popular Filters
Trials for PsA Patients
Monoclonal Antibodies
Guselkumab vs Golimumab for Psoriatic Arthritis
This trial will compare two medications, guselkumab and golimumab, in patients with psoriatic arthritis who did not respond well to their initial treatment. The goal is to see if switching to guselkumab is more effective than trying another similar medication. Guselkumab is used for treating moderate-to-severe plaque psoriasis in adults and has shown additional benefits in patients who did not respond well to other treatments.
Monoclonal Antibodies
Guselkumab for Psoriatic Arthritis
This trial is testing guselkumab, a medication that reduces inflammation, in patients with psoriatic arthritis affecting the spine. It works by blocking a protein called IL-23 to help reduce symptoms and inflammation. Guselkumab is the first IL-23 specific inhibitor approved for the treatment of moderate-to-severe psoriasis.
Trials for Psoriasis Patients
Monoclonal Antibodies
Guselkumab for Psoriatic Arthritis
This trial is testing guselkumab, a medication that reduces inflammation, in patients with psoriatic arthritis affecting the spine. It works by blocking a protein called IL-23 to help reduce symptoms and inflammation. Guselkumab is the first IL-23 specific inhibitor approved for the treatment of moderate-to-severe psoriasis.
Phase 3 Trials
Monoclonal Antibodies
Guselkumab vs Golimumab for Psoriatic Arthritis
This trial will compare two medications, guselkumab and golimumab, in patients with psoriatic arthritis who did not respond well to their initial treatment. The goal is to see if switching to guselkumab is more effective than trying another similar medication. Guselkumab is used for treating moderate-to-severe plaque psoriasis in adults and has shown additional benefits in patients who did not respond well to other treatments.
Trials With No Placebo
Monoclonal Antibodies
Guselkumab vs Golimumab for Psoriatic Arthritis
This trial will compare two medications, guselkumab and golimumab, in patients with psoriatic arthritis who did not respond well to their initial treatment. The goal is to see if switching to guselkumab is more effective than trying another similar medication. Guselkumab is used for treating moderate-to-severe plaque psoriasis in adults and has shown additional benefits in patients who did not respond well to other treatments.
Procedure
Ulcer Healing Analysis for Inflammatory Bowel Disease
This trial involves taking small pieces of tissue from the colon to study how ulcers heal. It includes patients with inflammatory bowel disease, arthritis, and healthy individuals to compare healing processes. Researchers will examine how genes work and how cells produce energy to understand healing.
View More Related Trials
Frequently Asked Questions
Introduction to psoriatic arthritis
What are the top hospitals conducting psoriatic arthritis research?
When it comes to cutting-edge research and clinical trials for psoriatic arthritis, hospitals across the United States are actively working to find new treatment options. In Philadelphia, the University of Pennsylvania is leading the way with four ongoing trials focused on psoriatic arthritis. This renowned institution has a total of four recorded trials in this field since they started their first investigation in 2019. Down in Tomball, Texas, DM Clinical Research is also making significant contributions with four active psoriatic arthritis trials and a matching tally of completed studies since their inaugural trial in 2020.
Moving westward to Phoenix, Arizona Arthritis and Rheumatology Research, PLLC is dedicated to advancing knowledge about psoriatic arthritis through three ongoing clinical trials. With a relatively recent start date in 2021, this institute shows promise as they continue their efforts towards better understanding and treating this condition. Similarly committed to researching psoriatic arthritis are the healthcare professionals at Bay Pines VA Healthcare System in Bay Pines, Florida. They too have three active clinical trials focused on this specific form of arthritis dating back to 2021.
Finally, located beachside in Huntington Beach, California's Newport Huntington Medical Group joins the ranks with three current psoriatic arthritis trials under its belt since recording its first trial also just last year (in 2021). These hospitals may vary geographically but share a common goal: improving the lives of those affected by psoriatic arthritis through groundbreaking research.
Psoriatic arthritis affects millions around the world—an inflammatory condition that causes joint pain and stiffness often accompanied by skin changes like patches or scales. As researchers delve deeper into these clinical investigations across different locations within America's medical landscape; they bring hope not only for patients themselves but also for future generations who will benefit from advancements made today
Which are the best cities for psoriatic arthritis clinical trials?
In the realm of psoriatic arthritis clinical trials, several cities stand out as hubs for research and development. Phoenix, Arizona takes the lead with 17 active studies focusing on promising treatments like Upadacitinib, Guselkumab, and TILD. Tampa, Florida follows closely behind with 13 ongoing trials investigating medications such as Upadacitinib, Risankizumab, and Guselkumab. Duncansville in Pennsylvania also shows promise with 11 active trials exploring options like Risankizumab and Upadacitinib. While New york City and Mesquite in Texas each host 10 ongoing studies targeting various medications including Ustekinumab, Nivolumab, Guselkumab, VTX958 Dose A among others. These cities serve as beacons of hope for individuals seeking participation in cutting-edge psoriatic arthritis clinical trials that may pave the path towards improved treatment outcomes.
Which are the top treatments for psoriatic arthritis being explored in clinical trials?
Clinical trials are paving the way for advancements in the treatment of psoriatic arthritis. Among the top contenders are guselkumab and ustekinumab, both currently involved in multiple active trials. Guselkumab has shown promise with four ongoing studies and a total of 12 psoriatic arthritis trials since its introduction in 2013. Ustekinumab, on the other hand, is being tested in three active trials and has accumulated 11 all-time trials dedicated to this condition since its listing seven years ago. Newcomer deucravacitinib is also making waves with two current clinical trials, having entered the scene just this year. Additionally, TILD and risankizumab show potential as they each participate in two active psoriatic arthritis studies. These treatments offer hope for improving outcomes and quality of life for individuals living with this challenging condition.
What are the most recent clinical trials for psoriatic arthritis?
Exciting advancements in the treatment of psoriatic arthritis have emerged from recent clinical trials. Notably, GUS has entered Phase 3, offering hope for improved outcomes and relief for patients with this condition. In addition, guselkumab prefilled syringe (Tremfya) has also shown promise in Phase 3 trials as a potential therapy for psoriatic arthritis patients. Another noteworthy development is VTX958 Dose A, which has progressed to Phase 2 trials. Lastly, sonelokimab dose regimen 1 and Group 1 are both undergoing Phase 2 and Phase 3 testing respectively. These groundbreaking studies bring us closer to more effective treatments that can significantly enhance the lives of individuals living with psoriatic arthritis.
What psoriatic arthritis clinical trials were recently completed?
Recent clinical trials have made significant strides in the field of psoriatic arthritis, offering hope for improved treatments. Takeda's trial investigating NDI-034858 concluded in January 2022, while UCB Biopharma SRL completed two trials: one on certolizumab pegol pharmacokinetics in June 2020 and another on Bimekizumab in April 2019. Additionally, Amgen's trial exploring Apremilast (CC-10004) wrapped up its research in December 2018. These advancements showcase the commitment of researchers to addressing the challenges posed by psoriatic arthritis and provide valuable insights into potential therapeutic options for patients affected by this condition.